Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Mascola, John R.; Stiegler, Gabriela; VanCott, Thomas C.; Katinger, Hermann; Carpenter, Calvin B.; Hanson, Chris E.; Beary, Holly; Hayes, Deborah; Frankel, Sarah S.; Birx, Deborah L.; Lewis, Mark G.

doi:10.1097/00002030-200102001-00018

Cited by 465 publications

(626 citation statements)

References 0 publications

Supporting

Mentioning

604

Contrasting

Unclassified

Order By: Relevance

“…For analysis of HIV-specific B cell responses, 1 ϫ 10 5 spleen cells were cultured in 200 l of RPMI 1640 supplemented with 5% inactivated FCS at 37°C in 96-well, flat-bottom plates (Nunc) with rgp160 (1 g/ml) or peptides (10 g/ml) for 72 h. After washing, Ag-specific Igs were measured by ELISA as described above (14,26). A positive reactivity was considered if the ELISA substrate absorbance was higher than the mean value OD Ϯ 2 SD of the negative control.…”

Section: B and T Cell Memory Igg/iga Synthesis And T Cell Proliferamentioning

confidence: 99%

See 1 more Smart Citation

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Devito

Zuber

Schröder³

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

An intranasal DNA vaccine prime followed by a gp41 peptide booster immunization was compared with gp41 peptide and control immunizations. Serum HIV-1-specific IgG and IgA as well as IgA in feces and vaginal and lung secretions were detected after immunizations. Long-term humoral immunity was studied for up to 12 mo after the booster immunization by testing the presence of HIV-1 gp41- and CCR5-specific Abs and IgG/IgA-secreting B lymphocytes in spleen and regional lymph nodes in immunized mice. A long-term IgA-specific response in the intestines, vagina, and lungs was obtained in addition to a systemic immune response. Mice immunized only with gp41 peptides and L3 adjuvant developed a long-term gp41-specific serum IgG response systemically, although over a shorter period (1–9 mo), and long-term mucosal gp41-specific IgA immunity. HIV-1-neutralizing serum Abs were induced that were still present 12 mo after booster immunization. HIV-1 SF2-neutralizing fecal and lung IgA was detectable only in the DNA-primed mouse groups. Intranasal DNA prime followed by one peptide/L3 adjuvant booster immunization, but not a peptide prime followed by a DNA booster, was able to induce B cell memory and HIV-1-neutralizing Abs for at least half of a mouse’s life span.

show abstract

Section: B and T Cell Memory Igg/iga Synthesis And T Cell Proliferamentioning

confidence: 99%

“…DNA constructs encoding multi-CTL epitopes from human, macaques, and mice have also been administrated i.m., enhancing HIV-specific CTL epitopes (13). Abs have been administrated to prevent HIV transmission, such as mAbs 2F5 and 2G12, which protected macaques against SHIV vaginal challenge (14).…”

mentioning

confidence: 99%

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Devito

Zuber

Schröder³

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…The two NAbs b12 and 2G12 are directed against exterior gp120 protein [7][8][9][10][11], and the three NAbs 2F5, 4E10 and Z13 are directed against the transmembrane gp41 protein [12][13][14]. Passive immunotherapy studies using combinations of some of these mAbs have resulted in protection against intravenous and/or mucosal simianhuman immunodeficiency virus (SHIV) challenge in monkeys [15][16][17][18], In addition, 2F5 and/ or 4E10 plus 2G12 immunotherapy have resulted in reduced viremia in established HIV-1 infection or delay of HIV-1 rebound in individuals undergoing interrupted antiretroviral treatment (ART) [19,20].…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

Kim

Qiao

et al. 2007

Vaccine

View full text Add to dashboard Cite

The conserved membrane proximal external region (MPER) of the ectodomain of human immunodeficiency virus type 1 (HIV-1) gp41 is the target of two broadly neutralizing antibodies, 2F5 and 4E10. However, no neutralizing antibodies have been elicited against immunogens bearing these epitopes. Given that structural and biochemical studies suggest that the lipid membrane of the virion is involved in their proper configuration, HIV-1 gp41 derivatives in a pre-fusion state were expressed on the surface of immature virus like particles (VLP) derived from Sf9 cells. Guinea pigs were immunized with three doses of VLPs or Sf9 cells presenting gp41 derivatives with or without E. coli heat-labile enterotoxin (LT) as an adjuvant. While immune sera contained high titer anti-VLP antibodies, the specific anti-gp41 antibody responses were low with no neutralizing antibodies detected. An explanation for this absence may be the low level of gp41 expression relative to the many other proteins derived from host cells which are incorporated onto the VLP surface. In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance.

show abstract

“…However, the relative importance of mobilizing each arm of the immune system and the means to induce each type of immunity are unclear. Although several successful passive immunization studies using neutralizing monoclonal antibodies in macaques strongly suggest that inducing broadly reactive neutralizing antibodies as part of any vaccine regimen would be beneficial [1][2][3][4][5], the levels and breadth of neutralizing antibodies induced by active vaccination have thus far proved insufficient to protect against infection [6][7][8]. It appears necessary that a vaccine must activate both cellular and humoral immune mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys

Jiang

Rasmussen

Nolan

et al. 2007

Vaccine

View full text Add to dashboard Cite

Induction of strong cellular immunity will be important for AIDS vaccine candidates. Natural infection with wild-type Listeria monocytogenes (Lm), an orally transmitted organism, is known to generate strong cellular immunity, thus raising the possibility that live attenuated Lm could serve as a vaccine vector. We sought to examine the potential of live attenuated Lm to induce cellular immune responses to HIV Gag. Rhesus macaques were immunized with Lmdd-gag that expresses HIV gag and lacks two genes in the D-alanine (D-ala) synthesis pathway. Without this key component of the bacterial cell wall, vaccine vector replication critically depends on exogenous D-ala. Lmdd-gag was given to animals either solely orally or by oral priming followed by intramuscular (i.m.) boosting; D-ala was co-administered with all vaccinations. Lmdd-gag and D-ala were well tolerated. Oral priming/oral boosting induced Gag-specific cellular immune responses, whereas oral priming/i.m. boosting induced systemic as well as mucosal anti-Gag antibodies. These results suggest that the route of vaccination may bias anti-Gag immune responses either towards T-helper type 1 (Th1) or Th2 responses; overall, our data show that live attenuated, recombinant Lmdd-gag was safe and immunogenic in primates.

show abstract

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Cited by 465 publications

References 0 publications

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys

Contact Info

Product

Resources

About